Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
There will be 2 phases in this study. Patients will either be enrolled to the first phase or
to the second phase, depending upon when they enroll into the study.
The first phase of this study is done to evaluate the safety of enzastaurin in patients. This
is done by gradually increasing the dose of the drug in small groups of patients and watching
closely for side effects.
In the second phase of the study, the dose determined to be safe will be used with
temozolomide during and following radiation therapy to see if the combination can help
patients with brain tumors live longer.